Latest news with #MDNA55
Hamilton Spectator
31-07-2025
- Business
- Hamilton Spectator
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. ('Medicenna' or the 'Company') (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today announced grant of five patents covering the Company's IL-2 and IL-4 Superkine platforms. These patents strengthen Medicenna's intellectual property (IP) position across key markets and further support the Company's lead clinical and preclinical programs. The newly granted patents cover composition, formulation, combination, use, and therapeutic applications of IL-2 and IL-4 Superkines. Newly granted patents span major markets, with anticipated expiration dates ranging from 2033 to 2040 depending on the specific case and local rules, without accounting for any potential extensions. Patents granted include: 'These newly granted and allowed patents not only expand the breadth and depth of our intellectual property portfolio but also enhance the long-term commercial potential of our Superkine programs,' said Fahar Merchant, Ph.D., President and CEO of Medicenna. 'Notably, the patent covering IL-2 superagonists in combination with anti-PD1 antibodies provides important coverage for MDNA11, which is being evaluated in the ongoing Phase 1/2 ABILITY-1 study, reinforcing both the clinical rationale and commercial potential. Furthermore, protection granted to a novel formulation of bizaxofusp (MDNA55), used in the Phase 2b recurrent glioblastoma clinical trial, solidifies its commercial exclusivity for treatment of brain cancers as we pursue potential partnering of this Phase 3 ready asset. By strengthening long-term protection for our proprietary IL-2 and IL-4 assets across key jurisdictions, we are laying the foundation for durable competitive advantage and sustained shareholder value. We look forward to sharing additional clinical data from the ABILITY-1 clinical trial during the balance of this calendar year.' Medicenna's global IP portfolio now comprises 86 granted or allowed patents, supporting a robust and diverse clinical pipeline. About Medicenna Therapeutics Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna's early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically 'cold' tumors. For more information, please visit , and follow us on X and LinkedIn . Forward-Looking Statements This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook, intellectual property protection, clinical and commercial potential, competitive position and shareholder value creation or or other statements that are not historical facts. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expect', 'believe', 'seek', 'potentially' and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements. This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release. Investor/Media Contact: Shushu Feng Investor Relations, Medicenna Therapeutics ir@
Yahoo
19-05-2025
- Business
- Yahoo
Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034)
As per DelveInsight's estimates, among the 7MM, the US captured the highest market of intra-tumoral cancer therapies of nearly USD 74 million in 2024, which is expected to increase due to the launch of emerging therapies such as CAN-2409, RP1 (vusolimogene oderparepvec), SP-002 (ASN-002), Bizaxofusp (MDNA55), and others. LAS VEGAS, May 19, 2025 /PRNewswire/ -- DelveInsight's Intra-tumoral Cancer Therapies Market report includes a comprehensive understanding of current treatment practices, emerging intra-tumoral cancer therapies, market share of individual therapies, and current and forecasted intra-tumoral cancer therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Intra-tumoral Cancer Therapies Market Report Currently, only three Intra-tumoral Cancer Therapies are approved; namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen), approved in the US and Europe in 2015, DELYTACT (teserpaturev/G47Δ; Daiichi Sankyo) approved in Japan in 2021, and HENSIFY in Europe in 2019. As per DelveInsight's analysis, the total market size of intra-tumoral cancer therapies in the 7MM was USD 109 million in 2024 and is projected to grow during the forecast period (2025-2034). In 2024, the total cases of selected indication (based on current landscape and pipeline activity) were 8.9 million in the 7MM, which is anticipated to increase by 2034. Leading intra-tumoral cancer therapies companies, such as Janssen, Stamford Pharmaceuticals, Ascend Biopharmaceuticals, Replimune, Highlight Therapeutics, Cytovation ASA, Intensity Therapeutics, Ascendis Pharma, Treovir, Matica Biotechnology, QBiotics, NanOlogy, Lokon Pharma AB, EpicentRx, Medicenna Therapeutics, Philogen S.p.A., Candel Therapeutics, Lytix Biopharma, Verrica Pharmaceuticals, CEI-SCI, and others, and others, are developing novel intra-tumoral cancer therapies that are expected to enter the intra-tumoral cancer therapies market in the coming years. Some of the key intra-tumoral cancer therapies in the pipeline include INT230-6, Vusolimogene oderparepvec (RP1), Nidlegy (Daromun), G207, Ilixadencel (INTUVAX), Tigilanol tiglate, SP-002 (ASN-002), BO-112, Bizaxofusp (MDNA55), and others. In March 2025, NANOBIOTIX announced topline data from the completed dose-escalation portion of a Phase I study, conducted under the sponsorship of The University of Texas MD Anderson Cancer Center, evaluating JNJ-1900 (NBTXR3) activated by radiation therapy as a second-line or later (2L+) treatment for patients with locally advanced NSCLC eligible for re-irradiation. In March 2025, NANOBIOTIX announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV. The amendment removes NANOBIOTIX's funding obligation for NANORAY- 312 and releases Johnson & Johnson from select future potential milestone payments while safeguarding NANOBIOTIX's path to sustainable cash flow through significant potential milestone payments. In March 2025, Candel Therapeutics and IDEA Pharma announced a strategic commercial partnership. Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel's lead asset, CAN-2409. In January 2025, Lokon Pharma AB announced that the Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) for the company's product candidate LOAd703 for the treatment of pancreatic cancer. In January 2025, Intensity Therapeutics announced that the Data Monitoring Committee (DMC) recommended the continuation of its Phase III sarcoma trial (INT230-6, INVINCIBLE-3) without modification based on data reviewed from July 2024 to December 2024. Some factors, such as the precedence of failure of emerging therapies, insufficient knowledge about Intra-tumoral Cancer Therapies, and several other drawbacks, might hinder the Intra-tumoral Cancer Therapies market growth. Discover which therapies are expected to grab the intra-tumoral cancer therapies market share @ Intra-tumoral Cancer Therapies Market Report Intra-tumoral Cancer Therapies Market Dynamics The intra-tumoral cancer therapies market dynamics are expected to change in the coming years. Various classes of intra-tumoral immunotherapies, including radioenhancer nanoparticles, recombinant fusion proteins, oncolytic therapy, gene therapy, synthetic dsRNA complexes, and others, are currently in preclinical and clinical development. These therapies increase drug concentration and availability within the tumor microenvironment while limiting systemic exposure and reducing the likelihood of immune-related side effects in other parts of the body. Intra-tumoral therapeutic strategies offer a powerful approach to in situ vaccine development, utilizing immune-stimulating agents to trigger local and systemic anti-tumor immune responses. Additionally, the ability of intra-tumoral immunotherapy combinations to elicit both T-cell and B-cell antitumor responses presents a potential strategy to overcome immune escape mechanisms, such as the loss of HLA-I expression on tumor cells, which are often associated with immune checkpoint therapy monoclonal antibody monotherapies. Furthermore, potential therapies are being investigated, and it is safe to predict that the treatment space will significantly impact the intra-tumoral cancer therapies market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the intra-tumoral cancer therapies market in the 7MM. However, several factors may impede the growth of the intra-tumoral cancer therapies market. The lack of standardized guidelines for intra-tumoral immunotherapy delivery results in variations in lesion selection, injection frequency, and needle technique, which directly affect treatment outcomes and safety. Patients are required to visit clinics for each dosing session, and the administration necessitates both trained radiologists and logistics support alongside skilled physicians. While research into intra-tumoral therapies has grown in recent years, several therapies, such as tilsotolimod/Ipilimumab, sotigalimab (APX005M), and vidutolimod (CMP-001), have failed clinical trials, impacting the market. Additionally, tumors with high intra-tumoral heterogeneity may lead to poorer clinical outcomes for patients. Intra-tumoral Cancer Therapies Therapeutics Market Although significant progress has been made in cancer treatment through methods like surgery, chemotherapy, radiation, immunotherapy, and targeted therapies, many of these treatments still face limitations such as systemic toxicity, inadequate tumor penetration, and poor targeting. These issues contribute to high mortality rates, underscoring the need for more precise and localized treatment options. Recently, cancer treatment strategies have increasingly focused on alternative delivery methods, including intra-tumoral administration. This approach is being actively researched, with several therapeutic candidates—such as immune receptor agonists, viral therapies, fusion proteins, monoclonal antibodies, and gene therapies—currently undergoing preclinical and clinical trials. Intra-tumoral immunotherapy, which involves directly delivering agents into or near the tumor site, is emerging as a promising approach. This strategy aims to boost localized immune responses while reducing systemic side effects. The first oncolytic virus, IMLYGIC (T-Vec; Amgen), was approved by the US FDA for treating unresectable melanoma lesions after surgery, following a Phase III trial. The European Commission approved the treatment of advanced melanoma in 2015. In 2019, Nanobiotix's HENSIFY (NBTXR3), a hafnium oxide nanoparticle therapy combined with radiation, received European approval for soft tissue sarcoma, with plans for data releases through 2025-2026 across multiple cancers. For STS the drug is approved in Europe but not yet launched. In Japan, DELYTACT (G47∆; Daiichi Sankyo) was granted conditional approval for malignant glioma, marking the first oncolytic virus for brain cancer, and is still under evaluation for its clinical benefits. IMLYGIC from Amgen is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors. Despite the initial hype for this exciting intra-tumoral mode of cancer gene therapy, IMLYGIC's debut did not translate into much commercial success in the melanoma market. Limitations of the intra-tumoral administration, no statistically significant benefit in overall survival (OS), and the intense competition from immune checkpoint inhibitors (ICIs) due to their efficacy and manageable side effects are some of the main factors for ithe nsignificant revenues of this novel therapy. Learn more about the FDA-approved intra-tumoral cancer therapies @ Intra-tumoral Cancer Therapies Treatment Key Emerging Intra-tumoral Cancer Therapies and Companies The emerging pipeline of intra-tumoral cancer therapies is robust, including drugs from key players such as Candel Therapeutics (CAN-2409), Lytix Biopharma/Verrica Pharmaceuticals (LTX-315 [VP-315]), CEI-SCI (MULTIKINE), Philogen (Daromun [NIDLEGY; a combo of L19IL2 + L19TNF]), Replimune (RP2 and RP1 [vusolimogene oderparepvec]), Highlight Therapeutics (BO-112), Cytovation ASA (CY-101), Intensity Therapeutics (INT230-6), Ascendis Pharma (TransCon IL-2 β⁄γ), Treovir/Matica Biotechnology (G207), QBiotics (Tigilanol tiglate), NanOlogy (NanoPac), EpicentRx (AdAPT-001), Medicenna Therapeutics (Bizaxofusp [MDNA55]), and others. RP1 (vusolimogene oderparepvec), Replimune's lead product candidate, is based on a proprietary strain of Herpes Simplex Virus (HSV) engineered with a fusogenic protein (GALV-GP R-) and GM-CSF to enhance tumor killing potency, immunogenicity, and activation of a systemic antitumor immune response. In November 2024, Replimune announced that the FDA granted Breakthrough Therapy Designation (BTD) to RP1 in combination with nivolumab for the treatment of advanced melanoma in adult patients who have previously received an anti-PD1 regimen. Nidlegy is a biopharmaceutical product, proprietary to Philogen, designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF, which are manufactured independently and which are mixed prior to intralesional administration. In July 2024, Philogen and Sun Pharmaceutical announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy. CAN-2409 (Candel Therapeutics) is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV thymidine kinase (HSV-tk) gene to a patient's specific tumor and induce an individualized, systemic immune response against the tumor. In March 2025, according to the company's corporate highlights, the preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer are underway, with submission expected in Q4 2026. The anticipated launch of these emerging therapies are poised to transform the intra-tumoral cancer therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the intra-tumoral cancer therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about intra-tumoral cancer therapies clinical trials, visit @ Intra-tumoral Cancer Therapies Intra-tumoral Cancer Therapies Overview Cancer is a highly diverse disease, with its signs, symptoms, and treatments varying across different types, making it crucial to create targeted therapies for individual patients. Current treatment options for cancer include immunotherapy, radiotherapy, chemotherapy, targeted drug therapies, and more. While these approaches have improved OS and patient outcomes, they still have limitations and are not effective for everyone. Researchers are therefore working to develop new treatments that can overcome these challenges, with intra-tumoral cancer therapies emerging as a promising strategy. Intra-tumoral immunotherapy represents an innovative approach, where sophisticated antibodies are directly injected into tumors instead of being administered intravenously. This method focuses on delivering immunostimulatory agents straight into primary or metastatic tumor sites to initiate or enhance an antitumor immune response. Normally, the immune system detects and eliminates early tumors, but in immunosuppressive tumor environments, malignant cells can proliferate undetected. Regulatory T cells (Tregs), drawn to the tumor by chemokines, suppress Antigen-Presenting Cells (APCs) that would otherwise trigger an immune attack on tumor antigens. Moreover, tumor cells often release anti-inflammatory and regulatory cytokines like TGF-β and IL-10, which promote tumor growth and inhibit dendritic cell (DC) activation. To counteract this immunosuppressive environment, immunostimulants can be introduced. These agents work by attracting immune cells to the tumor or by activating the immune system to recognize and destroy cancer cells. Immunostimulants activate immune cells in the presence of tumor antigens, allowing them to travel to lymph nodes, where they stimulate tumor antigen-specific T cells through cross-presentation. These activated T cells can then return to the tumor or spread to distant tumors, leading to the targeted destruction of cancer cells. Intra-tumoral Cancer Therapies Epidemiology Segmentation In 2024, the total indication-wise treated cases of Intra-tumoral Cancer Therapies were 3.3 million in the 7MM, which is anticipated to increase by 2034. The intra-tumoral cancer therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of Selected Indications Indication-wise Target Patient Pool of Intra-tumoral Cancer Therapies Indication-wise Treated Cases of Intra-tumoral Cancer Therapies Intra-tumoral Cancer Therapies Report Metrics Details Study Period 2020–2034 Intra-tumoral Cancer Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Intra-tumoral Cancer Therapies Market CAGR (in the 7MM) 31.3 % Intra-tumoral Cancer Therapies Market Size in 2024 (in the 7MM) USD 109 Million Key Intra-tumoral Cancer Therapies Companies Amgen, Nanobiotix, Daiichi Sankyo, Janssen, Stamford Pharmaceuticals, Ascend Biopharmaceuticals, Replimune, Highlight Therapeutics, Cytovation ASA, Intensity Therapeutics, Ascendis Pharma, Treovir and Matica Biotechnology, QBiotics, NanOlogy, Lokon Pharma AB, EpicentRx, Medicenna Therapeutics, Philogen S.p.A., Candel Therapeutics, Lytix Biopharma, Verrica Pharmaceuticals, CEI-SCI, and others Key Intra-tumoral Cancer Therapies IMLYGIC (Talimogene Laherparepvec), DELYTACT (teserpaturev), HENSIFY, SP-002 (ASN-002), RP2, RP1 (vusolimogene oderparepvec), TransCon IL-2 β/γ, BO-112, CY-101, INT230-6, G207, Tigilanol Tiglate, NanoPac, LOAd703, AdAPT-001, Bizaxofusp (MDNA55), Nidlegy (L19IL2/L19TNF), CAN-2409, LTX-315, MULTIKINE and others. Scope of the Intra-tumoral Cancer Therapies Market Report Intra-tumoral Cancer Therapies Therapeutic Assessment: Intra-tumoral current marketed and emerging therapies Intra-tumoral Cancer Therapies Market Dynamics: Conjoint Analysis of Emerging Intra-tumoral Cancer Therapies Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Intra-tumoral Cancer Therapies Market Access and Reimbursement Discover more about intra-tumoral cancer therapies in development @ Intra-tumoral Cancer Therapies Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 Intra-tumoral Cancer Therapy Market Overview at a Glance 6.1 Market Share (%) Distribution by Indications of Intra-tumoral Cancer Therapies in 2025 6.2 Market Share (%) Distribution by Indications of Intra-tumoral Cancer Therapies in 2034 7 Background and Overview 7.1 Introduction 7.2 History of Intra-tumoral Cancer Therapies 7.3 Mechanism of Intra-tumoral Cancer Therapies 7.4 Tumor Properties to Consider for Intra-tumoral Cancer Therapies 7.5 Categories of Intra-tumoral Cancer Therapies 7.6 Advantages of Intra-tumoral Cancer Therapies 7.7 Limitations of Intra-tumoral Cancer Therapies 7.8 Emerging Therapies and Future Directions 8 Epidemiology and Patient Population 8.1 Key Findings 8.2 Assumptions and Rationale 8.3 Epidemiology Scenario in the 7MM 8.3.1 Total Cases of Selected Indications in the 7MM 8.3.2 Indication-wise Eligible Cases in the 7MM 8.3.3 Indication-wise Treated Cases in the 7MM 9 Marketed Therapies 9.1 Key Cross of Marketed Therapies 9.2 IMLYGIC (talimogene laherparepvec): Amgen 9.2.1 Product Description 9.2.2 Regulatory Milestones 9.2.3 Other Developmental Activities 9.2.4 Clinical Development Activities 9.2.4.1 Clinical Trials Information 9.2.5 Safety and Efficacy 9.2.6 Analyst View 9.3 DELYTACT (teserpaturev): Daiichi Sankyo 9.3.1 Product Description 9.3.2 Regulatory Milestones 9.3.3 Other Developmental Activities 9.3.4 Safety and Efficacy 9.3.5 Analyst View 10 Emerging Drugs 10.1 Key Competitors 10.2 HENSIFY (JNJ-1900, NBTXR3): NANOBIOTIX/Johnson & Johnson 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Clinical Development Activities 10.2.4.1 Clinical Trials Information 10.2.5 Safety and Efficacy 10.2.6 Analyst View 10.3 INT230-6: Intensity Therapeutics 10.3.1 Product Description 10.3.2 Other Development Activities 10.3.3 Clinical Development 10.3.3.1 Clinical Trial Information 10.3.4 Safety and Efficacy 10.3.5 Analyst View 10.4 RP1 (vusolimogene oderparepvec): Replimune 10.4.1 Product Description 10.4.2 Other Developmental Activities 10.4.3 Clinical Development 10.4.3.1 Clinical Trial Information 10.4.4 Safety and Efficacy 10.4.5 Analyst View 10.5 Nidlegy (Daromun): Philogen S.p.A 10.5.1 Product Description 10.5.2 Other Developmental Activities 10.5.3 Clinical Development 10.5.3.1 Clinical Trials Information 10.5.4 Safety and Efficacy 10.5.5 Analyst View 10.6 RP2: Replimune 10.6.1 Product Description 10.6.2 Other Developmental Activities 10.6.3 Clinical Development 10.6.3.1 Clinical Trial Information 10.6.4 Safety and Efficacy 10.6.5 Analyst View 10.7 Cotsiranib (STP705): Sirnaomics 10.7.1 Product Description 10.7.2 Other Development Activity 10.7.3 Clinical Development 10.7.3.1 Clinical Trial Information 10.7.4 Safety and Efficacy 10.7.5 Analyst View 10.8 BO-112: Highlight Therapeutics 10.8.1 Product Description 10.8.2 Other Developmental Activities 10.8.3 Clinical Development 10.8.3.1 Clinical Trial Information 10.8.4 Safety and Efficacy 10.8.5 Analyst View 10.9 SP-002 (ASN-002): Stamford Pharmaceuticals/Ascend Biopharmaceuticals 10.9.1 Product Description 10.9.2 Other Developmental Activities 10.9.3 Clinical Development 10.9.3.1 Clinical Trial Information 10.9.4 Safety and Efficacy 10.9.5 Analyst View 10.10 TransCon IL-2 β/γ: Ascendis Pharma 10.10.1 Product Description 10.10.2 Other Development Activity 10.10.3 Clinical Development 10.10.3.1 Clinical Trial Information 10.10.4 Safety and Efficacy 10.10.5 Analyst View 10.11 Ilixadencel (INTUVAX): Mendus 10.11.1 Product Description 10.11.2 Other Developmental Activities 10.11.3 Clinical Development 10.11.3.1 Clinical Trial Information 10.11.4 Safety and Efficacy 10.11.5 Analyst View 10.12 Tigilanol Tiglate: QBiotics 10.12.1 Product Description 10.12.2 Other Development Activity 10.12.3 Clinical Development 10.12.3.1 Clinical Trial Information 10.12.4 Safety and Efficacy 10.12.5 Analyst View 10.13 NanoPac (LSAM-PTX): NanOlogy 10.13.1 Product Description 10.13.2 Other Developmental Activities 10.13.3 Clinical Development 10.13.3.1 Clinical Trial Information 10.13.4 Safety and Efficacy 10.13.5 Analyst View 10.14 G207: Treovir and Matica Biotechnology 10.14.1 Product Description 10.14.2 Other Development Activities 10.14.3 Clinical Development 10.14.3.1 Clinical Trial Information 10.14.4 Safety and Efficacy 10.14.5 Analyst View 10.15 Lerapolturev: Istari Oncology 10.15.1 Product Description 10.15.2 Other Development Activities 10.15.3 Clinical Development 10.15.3.1 Clinical Trial Information 10.15.4 Safety and Efficacy 10.15.1 Analyst View 10.16 Nelitolimod (SD-101): TriSalus Life Sciences 10.16.1 Product Description 10.16.2 Other Developmental Activities 10.16.3 Clinical Development 10.16.3.1 Clinical Trial Information 10.16.4 Safety and Efficacy 10.16.5 Analyst View 10.17 LOAd703 (Delolimogene mupadenorepvec): Lokon Pharma AB 10.17.1 Product Description 10.17.2 Other Development Activity 10.17.3 Clinical Development 10.17.3.1 Clinical Trial Information 10.17.4 Safety and Efficacy 10.17.5 Analyst View 10.18 AdAPT-001: EpicentRx 10.18.1 Product Description 10.18.2 Other Developmental Activities 10.18.3 Clinical Development 10.18.3.1 Clinical Trial Information 10.18.4 Safety and Efficacy 10.18.5 Analyst View 10.19 Bizaxofusp (MDNA55): Medicenna Therapeutics 10.19.1 Product Description 10.19.2 Other Developmental Activities 10.19.3 Clinical Development 10.19.3.1 Clinical Trial Information 10.19.4 Safety and Efficacy 10.19.5 Analyst View 10.20 CY-101 (CyPep-1): Cytovation ASA 10.20.1 Product Description 10.20.2 Other Developmental Activities 10.20.3 Clinical Development 10.20.3.1 Clinical Trial Information 10.20.4 Safety and Efficacy 10.20.5 Analyst View 10.21 VG161: Virogin Biotech 10.21.1 Product Description 10.21.2 Other Developmental Activities 10.21.3 Clinical Development 10.21.3.1 Clinical Trial Information 10.21.4 Safety and Efficacy 10.21.5 Analyst View 10.22 CAN-2409: Candel Therapeutics 10.22.1 Product Description 10.22.2 Other Developmental Activities 10.22.3 Clinical Development 10.22.3.1 Clinical Trial Information 10.22.4 Safety and Efficacy 10.22.5 Analyst View 10.23 LTX-315: Lytix Biopharma 10.23.1 Product Description 10.23.2 Other Developmental Activities 10.23.3 Clinical Development 10.23.3.1 Clinical Trial Information 10.23.4 Safety and Efficacy 10.23.5 Analyst View 10.24 Multikine: CEI-SCI 10.24.1 Product Description 10.24.2 Other Developmental Activities 10.24.3 Clinical Development 10.24.3.1 Clinical Trial Information 10.24.4 Safety and Efficacy 10.24.5 Analyst View 11 Intra-tumoral Cancer Therapies: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook 11.3 Key Market Forecast Assumptions 11.3.1 Cost Assumptions and Rebates 11.3.2 Pricing Trends 11.3.3 Analogue Assessment 11.3.4 Launch Year and Therapy Uptakes 11.4 Conjoint Analysis 11.5 Total Market Size of Intra-tumoral Cancer Therapies by Indications in the 7MM 11.6 Total Market Size by Therapies in the 7MM 11.7 United States Market Size 11.7.1 Total Market Size of Intra-tumoral Cancer Therapies by Indications in the United States 11.7.2 Total Market Size by Therapies in the United States 11.8 EU4 and the UK Market Size 11.8.1 Total Market Size of Intra-tumoral Cancer Therapies by Indications in EU4 and the UK 11.8.2 Total Market Size by Therapies in EU4 and the UK 11.9 Japan 11.9.1 Total Market Size of Intra-tumoral Cancer Therapies by Indications in Japan 11.9.2 Total Market Size by Therapies in Japan 12 Unmet Needs 13 SWOT Analysis 14 KOL Views 15 Market Access and Reimbursement 15.1 The United States 15.1.1 Centre for Medicare and Medicaid Services (CMS) 15.2 EU4 and the UK 15.2.1 Germany 15.2.2 France 15.2.3 Italy 15.2.4 Spain 15.2.5 The United Kingdom 15.3 Japan 15.3.1 MHLW 15.5 Market Access and Reimbursement of Intra-tumoral Cancer Therapies 15.5.1 United States: Assistance programs 15.5.2 United Kingdom: The National Institute for Health and Care Excellence (NICE) Assessment 15.5.3 Germany: The Federal Joint Committee (G-BA) resolutions 15.5.4 Japan: Chuikyo Assessment 16 Appendix 16.1 Bibliography 16.2 Report Methodology 17 DelveInsight Capabilities 18 Disclaimer 19 About DelveInsight Related Reports Oncolytic Virus Market Oncolytic Virus Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of oncolytic virus, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oncolytic virus companies, including Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, among others. Oncolytic Virus Competitive Landscape Oncolytic Virus Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key oncolytic virus companies, including Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel Therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics, among others. Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key NSCLC companies including AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, among others. Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including Janssen Research and Development, Sanofi, AstraZeneca, Merck, Pfizer, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
